FindTrial
Sign In

Rucaparib camsylate

DRUG4 trials

Sponsors

University of Washington, pharmaand GmbH, Ohio State University Comprehensive Cancer Center, Alliance for Clinical Trials in Oncology

Conditions

ATM Gene MutationBRCA1 Gene MutationBRCA2 Gene MutationCastration Levels of TestosteroneCastration-Resistant Prostate CarcinomaFolate Receptor Alpha PositiveHomologous Recombination DeficiencyMetastatic Prostate Adenocarcinoma

Phase 1

Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
CompletedNCT03521037
pharmaand GmbHNeoplasms
Start: 2018-02-27End: 2021-02-24Updated: 2023-06-09
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
CompletedNCT03552471
Ohio State University Comprehensive Cancer CenterBRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive +7
Start: 2018-07-12End: 2022-12-19Updated: 2025-02-13

Phase 2

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
TerminatedNCT03442556
University of WashingtonATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation +7
Start: 2018-08-24End: 2025-06-04Updated: 2026-08-26

Phase 3

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Active, not recruitingNCT04455750
Alliance for Clinical Trials in OncologyCastration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVA Prostate Cancer AJCC v8 +2
Start: 2021-10-14End: 2027-09-01Updated: 2026-02-05

Related Papers

Final results of Alliance A031902: A phase III trial of enzalutamide plus rucaparib as first-line therapy in metastatic castration-resistant prostate cancer (CASPAR).
Journal of Clinical Oncology2026-05-27
PLATIPARP: A phase 2 study of induction docetaxel and carboplatin followed by maintenance rucaparib in treatment of patients with mCRPC with homologous recombination DNA repair deficiency.
Journal of Clinical Oncology2024-06-01
Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2023-02-205 citations
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2022-06-014 citations
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2022-02-165 citations
Abstract 445: Genomic characteristics and response to rucaparib and enzalutamide in the phase 1b RAMP study of metastatic castration-resistant prostate cancer (mCRPC) patients
Cancer Research2021-07-014 citations
CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2021-02-2016 citations
Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study.
Journal of Clinical Oncology2021-02-207 citations